in statements I, II and III in reply *to* Rajya Sabha Unstarred Question No. 51 for 25-4-1988.

Price increase of Vitamins A ana C

674. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of INDUSTRY be pleased to refer to the. answer to Unstarred Question 3529 given in the Rajya Sabha on 28th March, 1988 and state:

(a) whether it is a fact that his Ministry ,flxed the prices of Vitamins A and C under DPCO, 1979;

(b) if so, the names of units whose production was studied along) with the date of study and price recommended by BICP;

(c) when was the price notified for each;

(d) whether it is a fact that producers have increased. the prices of these drugs:

(e) if so, the price under DPCO, 1979, present price and percentage increase in each case;

(f) whether it is a fact that number of representations have baen submitted for inclusion . of these drugs under price control;

(g) whether it is also a fact that Kelker Committee recommended for price control of these drugs and have also confirmed their recommendation in reply to those who submitted representations; and

(h) if *so,* how his Ministry has exempted these drugs from price control?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO). (a) Yea, Sir. .

(b) to (e) The required details t& the extent of information, are given

			Price fixed under DPCO lOTQ	Current	
J.	Vitamin A Acetate Dry Powder 0.5 MlU/gm	1000 MIU	1297.86	2100.00	61.8
IT.	Vit. A Palmitate 1 MlU/gm HI,	1000 MIU	990.35	1300.00	31.2
Vit. A Palmitate . IV.	Vitamin B	1000 MIU	1020.67	1300.00	27.4
(1.7 MIU/gm)				*320.00*	45.8

(Ambalal Sarahhai Ltd)

(f) to (h) The requisite information has already been furnished to the Rajya Sabha in reply to the Unstarred Question No. 51 on 25th April 1988.

Production of Noosporla range __ formulations

675. SHRI CHANDRDYA PRASAD TRIPATHI: -Will the Minister of INDUSTRY "be nleased to state: .

(a) what is the composition of Neosporin, Avaforen, Acetan, Gly-nase, ndamin; Nebasulf, Flucort, Leadercort, Maftal, Naprosyn Arta-gen, Equagesic, Actifed, Arflur; Mclleril and fosipan along with the name of the manufacturer and therapeutic indication of each;

(b) names of bulk drugs going into the manufacture of these medicines allowed for production alone with